Literature DB >> 10499239

Moxidectin in cattle: correlation between plasma and target tissues disposition.

A Lifschitz1, G Virkel, F Imperiale, J F Sutra, P Galtier, C Lanusse, M Alvinerie.   

Abstract

The time of parasite exposure to active drug concentrations determines the persistence of the antiparasitic activity of endectocide compounds. This study evaluates the disposition kinetics of moxidectin (MXD) in plasma and in different target tissues following its subcutaneous (s.c.) administration to cattle. Eighteen male, 10-month old Holstein calves weighing 120-140 kg were subcutaneously injected in the shoulder area with a commercially available formulation of MXD (Cydectin 1%, American Cyanamid, Wayne, NJ, USA) at 200 micrograms/kg. Two treated calves were killed at each of the following times post-treatment: 1, 4, 8, 18, 28, 38, 48, 58 and 68 days. Abomasal and small intestine mucosal tissue and fluids, bile, faeces, lung, skin and plasma samples were collected, extracted, derivatized and analysed to determine MXD concentrations by high performance liquid chromatography (HPLC) with fluorescence detection. MXD was extensively distributed to all tissues and fluids analysed, being detected (concentrations > 0.1 ng/g; ng/mL) between 1 and 58 days post-treatment. MXD peak concentrations were attained during the first sampling day. MXD maximum concentration (Cmax) values ranged from 52.9 (intestinal mucosa) up to 149 ng/g (faeces). The mean residence time (MRT) in the different tissues and fluids ranged from 6.8 (abomasal mucosa) up to 11.3 (bile) days. MXD concentrations in abomasal and intestinal mucosal tissue were higher than those detected in plasma; however, there was a high correlation between MXD concentrations observed in plasma and those detected in both gastrointestinal mucosal tissues. MXD concentrations were markedly greater in the mucosa than in its respective digestive fluid (P < 0.01). MXD concentrations in skin were higher than those found in plasma (P < 0.01). Drug concentrations recovered in the dermis were greater than those detected in the hypodermal tissue (P < 0.05). Large concentrations of MXD were excreted in bile and faeces. These findings may contribute to an understanding of the relationship between the kinetic behaviour and the persistence of the antiparasite activity of MXD against different ecto-endoparasites in cattle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499239     DOI: 10.1046/j.1365-2885.1999.00222.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  12 in total

1.  The influence of parasitism on the pharmacokinetics of moxidectin in lambs.

Authors:  Anne Lespine; Jean-François Sutra; Jacques Dupuy; Michel Alvinerie; Gilles Aumont
Journal:  Parasitol Res       Date:  2004-05-01       Impact factor: 2.289

Review 2.  A review on the toxicity and non-target effects of macrocyclic lactones in terrestrial and aquatic environments.

Authors:  Jean-Pierre Lumaret; Faiek Errouissi; Kevin Floate; Jörg Römbke; Keith Wardhaugh
Journal:  Curr Pharm Biotechnol       Date:  2012-05       Impact factor: 2.837

3.  Gene expression analysis of ABC transporters in a resistant Cooperia oncophora isolate following in vivo and in vitro exposure to macrocyclic lactones.

Authors:  J De Graef; J Demeler; P Skuce; M Mitreva; G Von Samson-Himmelstjerna; J Vercruysse; E Claerebout; P Geldhof
Journal:  Parasitology       Date:  2013-01-02       Impact factor: 3.234

4.  Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation.

Authors:  Charlotte Bernigaud; Fang Fang; Olivier Chosidow; Jacques Guillot; Katja Fischer; Anne Lespine; Ludwig S Aho; Amanda J Mullins; Berhane Tecle; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Frédéric Beugnet; Françoise Botterel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei.

Authors:  Kate E Mounsey; Shelley F Walton; Ashlee Innes; Skye Cash-Deans; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Enhancement of oral moxidectin bioavailability in rabbits by lipid co-administration.

Authors:  Mohamad Firas Bassissi; Anne Lespine; Michel Alvinerie
Journal:  Parasitol Res       Date:  2004-08-26       Impact factor: 2.289

Review 7.  Endectocide use in cattle and fecal residues: environmental effects in Canada.

Authors:  Kevin D Floate
Journal:  Can J Vet Res       Date:  2006-01       Impact factor: 1.310

Review 8.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

9.  Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.

Authors:  Nicole Scherr; Gerd Pluschke; Charles J Thompson; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2015-08-13

10.  Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model.

Authors:  Charlotte Bernigaud; Fang Fang; Katja Fischer; Anne Lespine; Ludwig Serge Aho; Dominique Dreau; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Françoise Botterel; Jacques Guillot; Olivier Chosidow
Journal:  PLoS Negl Trop Dis       Date:  2016-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.